For peroxisomal biogenesis disorders, premature termination codon mutations in PEX2 and PEX12 have previously been analyzed showing improved metabolic activity after G418 treatment [29]. The gene discussed is PEX2; the disease is Peroxisome biogenesis disorder-Zellweger syndrome spectrum.